Andon Health Co., Ltd.

The company takes the promotion of the new model of diabetes diagnosis and care "O+O" in China and the United States and the explosion of products as its two core strategies. The company has been engaged in the medical device industry for nearly 30 years, with sphygmomanometer, blood glucose meter and thermometer as the main products. The brands of "Andon" and "iHealth" have accumulated a good reputation and reputation at home and abroad. In recent years, with the iHealth thermometer, kits sold in the United States, has gradually formed a brand advantage, iHealth brand of the Internet of Things sphygmomanometer, thermometer, welcomed by users, in the United States Amazon e-commerce platform sales good. In the future, the company will introduce China's competitive technologies and products to the US market according to market demand. In terms of Internet medical care, the company takes the lead in implementing the core strategy of Internet + medical care with diabetes management as the entry point, helping the comprehensive care of the whole course of diabetes, and accelerating the promotion of the new model of diabetes diagnosis and treatment "O+O" in China and the United States. The essence of medical treatment is to improve treatment effect and reduce treatment cost. We believe that medical services will definitely extend from the hospital to the family. The new model of diabetes diagnosis and care "O+O" emphasizes the continuity of medical care services, offline is the starting point, online is the continuation and extension, to provide long-term care programs for diabetes patients, and continue to provide real-time medical treatment and life intervention for diabetes patients. Solve the core problems that patients face in daily life that no one will manage, will not manage, and forget to manage. To better achieve cost reduction and efficiency enhancement, the company established a dedicated business team in 2024 to actively engage in the research and development of the “AIoT Diabetes Home Healthcare Assistant” project. Based on existing large models, the project aims to develop a vertical model that integrates cutting-edge AI technology to create an intelligent and personalized tool for diabetes chronic disease management. Leveraging the capabilities of large models, the project will help optimize the allocation of medical resources and improve the quality of primary healthcare services.At present, the company has good cash reserves, which can not only provide strong support for the implementation of the two core strategies of accelerating the promotion of explosive products and the implementation of the "O+O" new model of diabetes treatment and care in China and the United States, but also resist risks in the future when there is uncertainty. The company adheres to the concept of stable operation and strives to maintain and increase the value of assets. To provide a strong guarantee for the sustainable and healthy development of the company, which is in line with the common interests of shareholders and the company. The company has established an asset management department and hired experienced professionals in the field of asset management. The Company's wholly-owned subsidiary, Andon Hong Kong Co.,Limited, is a dedicated investment subsidiary engaged in asset management business with its own funds. In addition, the company has increased the scope of investment business, that is, to engage in investment activities and investment management with its own funds. In order to realize the long-term preservation and appreciation of assets, our investment team has been focusing on sound investment strategies, and making reference to the investment methods of more mainstream institutional investors in the world, including fixed income, equity, alternative assets and other multi-asset, multi-strategy diversified asset allocation.